BBCR helps orphan drug developers find direction in clinical trials involving biologics, biosimilars, small molecules, medical devices, and repurposing. BBCR consultants have the experience to guide you through the development process with a clinical plan and a regulatory strategy. Our team will empower you with medical insight, effective regulatory expertise, strategy, and streamlined early clinical […]
Translation Medicine and Epigenetics
In an ever-changing regulatory environment, the BBCR team of specialists in Orphan and Personalized Medicine can help clients identify areas of need or economic interest – and helps secure opportunities for treatments for rare diseases and precision medicine.
June 6th, 2022 | Translation Medicine and EpigeneticsBBCR has developed an approach to meet the challenges of researchers and innovators seeking a clearer path to market. Learn more about the advantages of our Strategic Clinical Innovation Organization (SCIO) concept.
December 15th, 2021 | Translation Medicine and EpigeneticsWe aim to transform the transition stage between pre-clinical and clinical endpoints with smart strategy that, at a minimum, redirects the costs to benefit patients. The FDA has been calling for a smarter, more innovative approach, and we believe SCIO is the integrative, multidisciplinary approach to deliver it. Why SCIO? Investing in Strategy Accelerate Patient […]
BBCR meets clients’ needs in the ever-changing regulatory environment. As specialists in Orphan and Personalized Medicine, BBCR helps clients identify areas of need or economic interest and helps them find homes for treatments for rare diseases and precision medicine.
August 2nd, 2021 | Translation Medicine and EpigeneticsBBCR helps orphan drug developers find direction in clinical trials involving biologics, biosimilars, small molecules, medical devices, and repurposing. BBCR consultants have the experience to guide you through the development process with a clinical plan and a regulatory strategy. Our team will empower you with medical insight, effective regulatory expertise, strategy, and streamlined early clinical […]